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A B S T R A C T
Squamous cell carcinoma (SCC) and keratoacanthoma (KA) are skin neoplasms of epithelial origin. In contrast to
clearly malignant skin neoplasm SCC, KA is an unusual cutaneous neoplasm with a tendency to regression. The distinc-
tion between these two neoplasms, on histological grounds only, is still a challenge. In order to investigate further and to
assess the possible differences in transforming growth factor-alpha (TGF-a) expression between SCC and KA, 40 of skin
tumor specimens, 20 cases of each SCC and KA were analyzed immunohystochemicaly. We have found a significant dif-
ference in staining patterns between KA and SCC. In KAs we have detected TGF-a staining mainly diffusely (90% of
cases) and without peripheral staining of cells in 1–2 layers (60% of cases). Contrary, there was a mostly patchy staining
(55% of cases) with peripheral staining of cells in 1–2 layers (100% of cases) in SCCs. Generally, differentiation between
KA and SCC can be based on clinical and histological ground, but the distinction between these two skin tumors could
sometimes be difficult. We have shown that these skin neoplasms could be differentiated based on staining patterns of
TGF-á expression, thus this method could aid in differentiation between these two closely related entities in clinical prac-
tice.
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Introduction
Squamous cell carcinoma (SCC) and keratoacantho-
ma (KA) are skin neoplasms of epithelial origin. Skin
SCC is a malignant tumor with ability to metastaze,
while KA is an unusual cutaneous neoplasm, previously
considered a precancerous lesion, that is destructive lo-
cally, but has tendency to regress and, generally, no abil-
ity to metastaze. Usually, the differentiation of these tu-
mors can easly be done clinically because of their fast
growth and characteristic appearence of KA. KA pres-
ents in a shape of molluscoid nodule with a keratin plug
in its centre, while SCC presents in the shape of nodule
or ulcer that does not heal during one-month-period or
longer. The problem arrises within pathohistological
analysis of these tumors that may have similar patho-
hystological characteristics. Pathohistological analysis of
cutaneous SCC revealed tumor lesion consisted of irregu-
lar masses of epidermal cells that infiltrate epidermis
and proliferate into dermis. Tumor masses consist of
cells that remind on spinous, keratinic and undifferenti-
ated (anaplastic, atypic) spinous cells. Anaplasticity of
these cells could be seen in the difference of cell size and
shape, hyperplasia of cells and hyperchromasia of nuclei,
absence of intercellular connections, keratinization of in-
dividual cells forming keratinized pearls and presence of
atypical mytoses. Keratinized pearls consist of concentric
layers of cells that show gradual improvement of kerati-
nization towards the centre of a pearl. The more the tu-
mor is malignant, the more anaplastic cells are found in
it. Only a correctly taken biopsy of a tumor can guarran-
tee appropriate diagnosis. Marginal biopsy of KA can not
present enough data for exclusion of SCC. Correct diag-
nosis of KA needs »architecture« of the lesion along with
cell characteristics. The early, proliferative stage of KA is
characterized by the presence of exoendophytic squa-
mous proliferation with a central keratin-filled crater
and the overlying epidermis extended around the crater.
In this stage, epidermal cells have an eosynophylic glass
– like shine, while in the dermis there was a strong in-
flammatory infiltrate. In developed lesions, epidermis is
lying arround the zone of keratinization in a shape of
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papillomatous proliferation. Anaplasticity of cells could
be seen on the periphery in 1 or 2 layers of basophylic
cells, while eosinophylic cells are situated at the base of
crater centre. In the involutive stage, proliferation is di-
minished and the proliferating epithelium tended to flat-
ten out, with diminished inflammation and fibrosis un-
derlying the base.
Therefore, immunohistochemical staining techniques
are more presents in their analysis today.
Transforming growth factor alpha (TGF-a) is a poly-
peptid found in the culture of retrovirally neoplastic
altereted fibroblasts. The term TGF-a originates from a
fact that this polypeptid can reversibly transform normal
fibroblasts of rat kidney. TGF-a has a molecular weight
that varies among 5 to 20 kDa. The structure of TGF-a is
a shape of triple running loops, with 3 disulphid connec-
tions that connect 2 molecules of cistein. The final loop
shows strong homologation with the epidermal growth
factor (EGF). TGF-a has been sintetized in normal kera-
tinocytes, and in other cell populations such as: cutane-
ous adnexes, muscles and in vascular walls, also its ex-
pression has been established in many tumors, mostly in
those of malignant potential1–6. The expression of TGF-a
in cutaneous keratinocytes and its effect on mytosis have
been established in psoriasis. The role of TGF-a in prolif-
eration of tumor cells does not depend on high level of ex-
pression of endogen TGF-a, but transformed cells can
show stronger answer on TGF-a because of higher num-
ber of receptors on cell surface or because of the activa-
tion of factors that play role in transduction of the signal.
To investigate further and to assess the possible dif-
ferences in TGF-a expression between SCC and KA im-
munohistochemical analyses were performed.
Materials and Methods
Patients and skin specimens
40 of skin tumor specimens, 20 cases of each SCC and
KA, were obtained from patients at Department of Der-
matovenereology, Rijeka University Hospital Center, by
probatory or total excision of skin changes performed in
local anestesia with 1–2% xylocaine solution. Obtained
samples were fixed with 10% buffered formaldehyde and
embedded in paraffin. 4 mm-thick sections were stained
with hematoxylin-eosin and two pathologists examined
each slide independently.
Immunohistochemical staining
The primary antibody solution was a 1:50 dilution of
monoclonal antibody TGF-a (MercK Biosciences, Calbio-
chem, catalogue number HCS05 Calbiochem, clon 213-
4.4). TGF-a immunostaining was performed as follows:
paraffin-embedded tissue sections were deparaffinized in
xylene and rehydrated by washing in absolute and di-
luted ethyl alcohol and distilled water. Staining was car-
ried out after sections were treated for antigen retrival
according to manufacturer’s instructons. This was fol-
lowed by standard ABC (avidin-biotin complex) proce-
dure for 2 hours and 10 minutes in DAKO Techmate
Immunostainer (Techmate Horizon, serial No. 30097,
LJL Biosystems Inc., USA).
The sections were examined at high power in order to
determine the type of staining as follows: diffuse, patchy,
negative-without peripheral staining, without peripheral
staining of cells in 1–2 layers, with peripheral staining of
cells, weak staining.
Statistics
Obtained results were statistically analysed using ÷2-
test. P values of less than 0.05 were considered statisti-
cally significant.
Results
Results of immunohistochemical staining by TGF-a
were obtained from material consisted of previously diag-
nosed skin neoplasms, 20 of each KA and SCC.
TGF-a staining could be detected mainly diffusely and
without peripheral staining of cells in 1–2 layers in KA as
shown in Figure 1. Contrary, we have detected mostly
patchy staining in SCCs examined with peripheral stain-
ing of cells in 1–2 layers as shown in Figure 2.
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Fig. 1. Immunohystochemical staining for TGF-a in kerato-
achanthoma. TGF-a staining could be detected mainly diffusely
and without peripheral staining of cells in 1-2 layers (x400).
Fig. 2. Immunohystochemical staining for TGF-a in squamous
cell carcinoma. TGF-a detection was mostly patchy in peripheral
part of cells in 1-2 layers (x400).
The frequency of different staining patterns in KA
and SCC was summarized and shown in Table 1.
There was a significant difference in TGF-a staining
between KA characterized by diffuse staining as com-
pared with SCC that was more often stained focally (÷2=
6.12, p=0.01). We have detected a significant difference
in frequency of TGF-á staining between KA and SCC de-
pending on peripheral staining in 1–2 layers, signifi-
cantly more common in SCC as compared with KA (÷2=
15.4; p=0.001).
Discussion
In literature, there are many controversies about the
question of whether KA is a variant of SCC or a unique
lesion. The distinction of KA from SCC on histological
grounds has been a matter of convention. KA is an un-
usual cutaneous neoplasm characterized by self-involu-
tion. Many studies have been undertaken in order to de-
velop a simple method for differentiation between KA
and SCC in everyday practice.
Coffey et al. established that normal human kerati-
nocytes produce TGF-a1. Gottlieb et al. found the pres-
ence of TGF-a in normal, hyperproliferative and malig-
nant keratinocytes2. Christensen et al. detected the
expression of TGF-a in SCC of oral cavity. The authors
detected TGF-a expression in all cases of primary SCCs
and three out of four metastases were also positive on
TGF-a. These investigations established the presence of
TGF-a in oral SCC and its metastases. The immuno-
reactivity of TGF-a on endothelial and mucoserous glan-
dular cells was also proven3,4. Ho et al. demonstrated
that the majority of KA could be differentiated from SCC
by different arrangement of expression of TGF-a in their
cells. In 90% of tumor samples, there was a lack of the ex-
pression of TGF-a in 1–2 layers of cells of KA tumor lob-
ules, there was 0% expression in SCC, while we found the
expression of 60% in KA. Ho et al. also demonstrated fo-
cal expression of TGF-a in 40% of SCC, while focal ex-
pression in KA was 0%6.
Obtained results showed focal expression of TGF-a in
45% cases of SCC and in 5% cases of KA. Other authors
established expression of TGF-a in SCC of head and
neck, in contrast to examined control group5,7,8. Previ-
ously, Grant et al. demonstrated strong membranal and
cytoplasmatic expression of TGF-a in 12 from 20 cases
(60%) of solar keratosis, and in 13 from 15 cases (86%) of
Bowen disease9. Today the differentiating KA from SCC
is being investigated using many immunohistochemical
techniques of staining. Tan et al. compared SCC and KA
using Bcl-x that is important anti-apoptotic member of
Bcl-2 family. The activity of Bcl-x was diffuse in 75% of
SCC, while in 95% of cases of KA the activity was tipically
situated in border zone of the middle and the upper
spinous keratinocytes. Their conclusion was that gener-
ally diffuse expression of Bcl-x in SCC significated its
aggressivity, while it was less expressed in the middle and
the upper keratinocytes of KA, and its action was re-
duced in regressive forms of KA10. Melendez et al. were
examining the expression of intercellular adhesion mole-
cule-1 (ICAM-1) and vascular adhesion molecule-1
(VCAM-1) in KA and SCC. ICAM-1 was more expressed
in developed KA, while in regressive forms the expres-
sion was not marked. It was considerably expressed in
poorly differentiated SCC, while only focally in well dif-
ferentiated SCC11. Some articles demonstrated the con-
nection between KA and SCC. Tran et al. demonstrated
that KA was a variant of SCC using immunohistoche-
mical staining with oncostatin (OSM – glycoprotein that
stimulates macrophages and T-lymphocytes)12. Muku-
nyadzi et al. used syndecan-1 (proteoglycan important
for intercellular and cellular adhesion of matrix), and
they demonstrated that it was similarly expressed in KA
and in situ SCC, but was differently expressed in invasive
SCC13. Takeda et al. demonstrated that KA and SCC
were different tumors using angiotensin II receptors in
differentiating these two tumors14. Asch et al. were using
stromelysin 3 (ST3- a member of metalloproteinase fam-
ily) and demonstrated its stronger presence in SCC ver-
sus KA15. Conolly et al. demonstrated the difference be-
tween SCC and subungual KA using p53 and Ki67
markers16. Slater et al. demonstrated that KA and SCC
were biochemically and pathogenetically differing, and
they established that these tumors were individual enti-
ties using anti-P2x7 immunohistochemical staining17.
Batinac et al. showed that apoptosis as assessed by M30
expression is related to malignant potential of KA and
SCC and cell proliferation and could also aid in differen-
tiation between these two closely related neoplasms18. It
has been previously suggested that new apoptosis-based
therapeutics regulating apoptotic mechanisms in kerati-
nocytes, mostly through enhancement of apoptosis, could
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TABLE 1
EXPRESSION OF TGF-a IN KERATOACANTHOMA AND SQUAMOUS CELL CARCINOMA
Staining type Keratoacanthoma Spinocellular carcinoma
Diffuse 18 (90%) 11 (55%)
Patchy 1 (5%) 9 (45%)
Negative – without peripheral staining 1 (5%) 0 (0%)
Without peripheral staining of cells in 1–2 layers 12 (60%) 0 (0%)
With peripheral staining of cells 7 (35%) 20 (100%)
Weak Staining 3 (1%) 1 (5%)
aid conventional therapy procedures undertaken in these
skin tumors19.
Today, differentiation between KA and SCC on histo-
logical ground is still a challenge, since the distinction
between these two skin tumors could sometimes be diffi-
cult. We have shown that these skin neoplasms could be
generally differentiated based on staining patterns of
TGF-á expression, thus this method, as well as other pre-
viously suggested routine immunohistochemical staining
techniques, could surely aid in differentiation between
these two closely related entities in clinical practice.
R E F E R E N C E S
1. COFFEY RJ, DERYNCK R, WILCOX JN, BRINGMAN TS, GOU-
STIN AS, MOSES HL, PITTELKOW MR, Nature, 328 (1987) 817. DOI:
10.1038/328817a0. — 2. GOTTLIEB AB, CHANG CK, POSNETT DN,
FANELLI B, TAM JP J Exp Med, 167 (1988) 670. DOI: 10.1084/jem.167.
2.670. — 3. CHRISTENSEN ME, THERKILDSEN MH, POULSEN SS,
BRETLAU P Acta Otolaryngol (Stockh), 113 (1993) 563. DOI: 10.3109/
00016489309135864. — 4. CHRISTENSEN ME, THERKILDSEN MH,
POULSEN SS, J Pathol, 169 (1993) 323. DOI: 10.1002/path.1711690308.
— 5. GRANDIS JR, TWEARDY DJ, J Cell Biochem Suppl, 17 (1993) 188.
DOI: 10.1002/jcb.240531027. — 6. HO T, HORN T, FINZI E, Arch Der-
matol, 127 (1991) 1167. DOI: 10.1001/archderm.1991.01680070067007.
— 7. GRANDIS JR, TWEARDY DJ, Cancer Res, 53 (1993) 3579. — 8.
GRANDIS JR, ZENG Q, TWEARDY DJ, Nature Med, 2 (1996) 237. DOI:
10.1038/nm0296-237. — 9. GRANT JJ, HOWES G, MCKEE HP, Clin Exp
Dermatol, 20 (1995) 208. DOI: 10.1111/j.1365-2230.1995.tb01303.x. — 10.
TAN KB, LEE YS, Histopathology, 55 (2009) 338. DOI: 10.1111/j.1365-
2559.2009.03375.x. — 11. MELENDEZ ND, SMOLLER BR, MORGAN
M, Mod Pathol, 16 (2003) 8. DOI: 10.1097/01. MP.0000043520.74056.CD.
— 12. TRAN TA, ROSS JS, SHEEHAN CE, CARLSON JA, Mod Pathol,
13 (2000) 427. DOI: 10.1038/modpathol.3880073 — 13. MUKUNYADZI P,
SANDERSON RD, FAN CY, SMOLLER BR, Mod Pathol, 15 (2002) 45.
DOI: 10.1038/modpathol.3880488. — 14. TAKEDA H, KONDO S, Am J
Pathol, 158 (2001)1633. DOI: 10.1016/S0002-9440(10)64119-3. — 15.
ASCH PH, BASSET P, ROOS M, GROSSHANS E, BELLOCQ JP, CRI-
BIER B, Am J Dermatopathol, 21 (1999) 146. DOI: 10.1097/00000372-
199904000-00006. — 16. CONNOLLY M, NARAYAN S, OXLEY J, DE
BERKER DA, Clin Exp Dermatol, 33 (2008) 625. DOI: 10.1111/j.1365
2230.2008.02785.x. — 17. SLATER M, BARDEN JA, Histopathology, 47
(2005) 170. DOI: 10.1111/j.1365-2559.2005.02155.x. — 18. BATINAC T,
ZAMOLO G, BRUMINI G, BILJAN D, PETRANOVI] D, TRO[ELJ-VU-
KI] B, Coll Antropol, 32 (2008) 499. — 19. BATINAC T, ZAMOLO G,
RU@I] A, PER[I] V, Coll Antropol, 31 (2007) 23.
L. ^abrijan
University of Rijeka, Rijeka University Hospital Center, Department of Dermatovenereology,
Kre{imirova 42, 51000 Rijeka, Croatia
e-mail: leo.cabrijan@ri.t-com.hr
RAZLIKOVANJE KERATOAKANTOMA I SPINOCELULARNOG KARCINOMA KO@E
KORISTE]I TGF-a
S A @ E T A K
Spinocelularni karcinom (SCC) i keratoakantom (KA) su ko`ni tumori podrijetla iz epitela. Za razliku od jasno
malignog tumora SCC, KA je neobi~na maligna tumorska tvorba ko`e s tendencijom regresije. Diferencijacija ova dva
tumora, na temelju histolo{ke analize predstavlja izazov. Cilj ove studije bio je istra`iti i utvrditi izra`ajnost i mogu}e
razlike u pojavnosti transformiraju}eg ~imbenika rasta-alpha (TGF-a) u SCC-a i KA. Imunohistokemijski smo ana-
lizirali 40 uzoraka tumora ko`e, po 20 uzoraka SCC i KA. Utvr|ena je zna~ajna razlika u izra`ajnosti TGF-a izme|u KA
i SCC. Imunohistokemijsko bojenje u KA bilo je, uglavnom difuzno (90% slu~ajeva) i bez perifernog bojenja stanica u
jednom do dva sloja (60% slu~ajeva). Suprotno, bojenje u SCC bilo je ve}inom krpi~asto (55% slu~ajeva) s perifernim
bojenjem stanica u 1-2 sloja stanica (100% slu~ajeva). Diferencijacija izme|u KA i SCC ve}inom je mogu}a na temelju
klini~ke slike i histolo{ke analize, ali je ponekad ote`ano razlikovanje ova dva ko`na tumora. Pokazali smo da je diferen-
cijacija ove dvije skupine tumora ko`e mogu}a analizom uzoraka izra`ajnosti TGF-a, te smatramo da ova histolo{ka
metoda mo`e pridonijeti u klini~koj praksi razlikovanja ova dva usko povezana ko`na tumora.
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